BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has received an average rating of “Buy” from the eleven ratings firms that are covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $8.17.
Several analysts have weighed in on the company. JMP Securities boosted their price objective on BioCryst Pharmaceuticals from $10.00 to $11.00 and gave the stock an “outperform” rating in a report on Friday. Barclays raised shares of BioCryst Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $4.00 to $7.00 in a research note on Tuesday, May 5th. Royal Bank of Canada reaffirmed a “hold” rating and issued a $4.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Thursday, May 7th. Zacks Investment Research cut shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, May 22nd. Finally, Needham & Company LLC reissued a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Wednesday, May 6th.
Shares of BCRX stock traded down $0.22 during trading hours on Tuesday, hitting $4.77. 8,437,806 shares of the company’s stock were exchanged, compared to its average volume of 8,304,512. BioCryst Pharmaceuticals has a 52 week low of $1.38 and a 52 week high of $6.29. The stock has a market cap of $878.47 million, a price-to-earnings ratio of -5.07 and a beta of 2.78. The company has a debt-to-equity ratio of 11.03, a current ratio of 1.35 and a quick ratio of 1.35. The stock’s 50-day moving average is $4.69 and its 200-day moving average is $3.35.
A number of institutional investors have recently modified their holdings of BCRX. Point72 Asset Management L.P. increased its stake in BioCryst Pharmaceuticals by 157.1% during the 4th quarter. Point72 Asset Management L.P. now owns 8,382,900 shares of the biotechnology company’s stock worth $28,921,000 after purchasing an additional 5,122,900 shares in the last quarter. UBS Group AG increased its position in shares of BioCryst Pharmaceuticals by 80.7% during the fourth quarter. UBS Group AG now owns 5,488,287 shares of the biotechnology company’s stock worth $18,935,000 after acquiring an additional 2,450,478 shares in the last quarter. Sofinnova Investments Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 316.3% during the fourth quarter. Sofinnova Investments Inc. now owns 2,151,164 shares of the biotechnology company’s stock worth $7,421,000 after acquiring an additional 1,634,430 shares during the period. BlackRock Inc. lifted its position in BioCryst Pharmaceuticals by 10.3% in the 1st quarter. BlackRock Inc. now owns 13,395,617 shares of the biotechnology company’s stock valued at $26,790,000 after acquiring an additional 1,245,406 shares in the last quarter. Finally, Parkman Healthcare Partners LLC acquired a new position in BioCryst Pharmaceuticals in the 4th quarter worth $3,937,000. 79.53% of the stock is currently owned by institutional investors and hedge funds.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.
Read More: Limitations of analyzing profit margin
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.